As the Trump administration’s Medicare and Medicaid fraud task force led by JD Vance continues expanding its investigations into benefits abuse across multiple states, a separate set of questions about COVID-era policy accountability resurfaced on Chicago’s Morning Answer when Steve Kirsch, tech entrepreneur, founder of the COVID-19 Early Treatment Fund, and executive director of the Vaccine Safety Research Foundation, joined Dan Proft to argue that meaningful reckoning with both the public health decisions of the pandemic era and the integrity of the data used to justify them remains largely absent from the current political conversation.
Kirsch made several claims about COVID vaccine safety and efficacy that depart significantly from the scientific and regulatory consensus, and which are disputed by the broader medical and public health research community. He argued that a phenomenon he called the healthy vaccinee effect, in which people who choose to get vaccinated tend to be healthier than those who do not independent of the vaccine itself, has been used to produce misleading efficacy statistics. He cited what he described as studies from Denmark, South Korea, and Israel suggesting that standard mortality comparisons between vaccinated and unvaccinated populations cannot reliably attribute health differences to the vaccines themselves without controlling for this pre-existing health disparity. Epidemiologists and public health researchers widely acknowledge the healthy vaccinee effect as a real methodological challenge requiring careful adjustment, though the prevailing scientific consensus, supported by large-scale randomized and observational studies, is that the COVID vaccines were effective at reducing severe illness and death, particularly among older and higher-risk populations.
Kirsch also raised disputed claims about reported adverse events, including referencing a memo by FDA official Vinay Prasad, which was disclosed by the Washington Post, that he said identified ten children determined to have died in connection with COVID vaccination. The status and interpretation of individual adverse event reports is a subject of ongoing scientific discussion, and regulators and independent researchers have continued to monitor vaccine safety signals. Prasad’s work at the FDA has itself been the subject of significant debate within the medical community regarding methodology and interpretation. Kirsch contrasted the attention given to nine reported deaths associated with raw milk, which became a focus of a congressional hearing with HHS Secretary Robert F. Kennedy Jr., with what he characterized as insufficient scrutiny of vaccine-related adverse event reports, an argument he said reflects a double standard in how public health agencies respond to different categories of safety concern.
On the broader question of data transparency, Kirsch argued that no country other than the Czech Republic has released individual-level data on COVID outcomes in ways that allow independent researchers to fully analyze the relationship between vaccination status and mortality. He said this opacity makes it impossible for the scientific community to reach definitive conclusions about long-term health outcomes across different vaccination cohorts, including people who received one, two, three, or more doses. This call for greater data transparency is shared by a range of researchers across the ideological spectrum, even those who disagree sharply with Kirsch’s broader conclusions about vaccine safety.
Kirsch also offered the disputed claim that studies comparing fully vaccinated and fully unvaccinated children consistently show better health outcomes in unvaccinated children across every measured metric. This claim is not supported by the mainstream pediatric and immunological research literature, which generally finds significant protective benefits from childhood vaccination against a range of serious diseases.
Both Kirsch and Proft expressed frustration that the political conversation about COVID-era policy accountability has largely dissipated, with Kirsch suggesting that Trump administration officials have been discouraged from pursuing vaccine-related questions partly because Trump views the rapid development of COVID vaccines as one of his signature first-term accomplishments. Kirsch said this political dynamic is constraining even officials like Kennedy who might otherwise be more willing to examine the question. He also argued that the Pfizer clinical trial data shows a statistically anomalous difference in protocol exclusions between the vaccinated and placebo arms that he said cannot be explained by random variation, a claim that independent biostatisticians and regulators have not validated to the same conclusion Kirsch draws from it.
These claims reflect a perspective that sits well outside the mainstream scientific and regulatory consensus on COVID vaccine safety and efficacy. Readers interested in the underlying research are encouraged to consult peer-reviewed literature and the published findings of regulatory agencies including the FDA and CDC, as well as independent analyses from academic institutions, which present a substantially different overall picture than Kirsch describes.